



Nissan Chemical
CORPORATION
WHERE IT ALL BEGINS

February 9, 2026

Presentation for Investors

3Q FY2025 (April 1, 2025 - December 31, 2025) Financial Results

Translation of presentation materials for the conference call held on February 9, 2026

Presented by DAIMON Hideki
Director, Senior Executive Vice President & CFO



Contents

01	3Q FY2025 Financial Results	P3
02	Segment Performance	P11
03	ESG Topics	P31
04	Appendix	P36

Contents

- 01
- 02
- 03
- 04

3Q FY2025 Financial Results	P3
Segment Performance	P11
ESG Topics	P31
Appendix	P36

3Q

vs. 3Q FY2024

- Sales up ¥8.7 billion (+15%)
- OP up ¥2.6 billion (+21%)
- Net Income up ¥1.0 billion (+9%)

1-3Q
Total¹

vs. 1-3Q
FY2024

- Sales up ¥20.6 billion (+12%)
- OP up ¥3.9 billion (+10%)
- Net Income up ¥3.3 billion (+11%)

1. Hereinafter referred to as 1-3Q

3Q

vs. 3Q Outlook
as of Nov 2025

- Sales above target ¥5.8 billion
- OP above target ¥3.4 billion
- Net Income above target ¥3.9 billion

Shareholder Returns

- Dividend ¥180/share (Full-Year)
【vs. FY2024】 up ¥6/share 【vs. Outlook as of Nov 2025】 unchanged
- Share Repurchase a ¥10.5 billion
¥1.5 billion (Announced in March 2025, Completed in April 2025)
¥9.0 billion (Announced in May 2025, Completed until February 2026)
- Total Payout Ratio Outlook 78.8%

FY2025 Outlook

- FY2025 Outlook for full year remain unchanged
from those announced in Nov 2025
(Outlook by segment also remain unchanged)

3Q FY2025 Financial Summary YOY Change

(¥billion)

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Sales	118.2	56.6	174.8	130.1	65.3	195.4	+11.9 (+10%)	+8.7 (+15%)	+20.6 (+12%)
Operating Profit	28.3	12.8	41.1	29.6	15.4	45.0	+1.3 (+4%)	+2.6 (+21%)	+3.9 (+10%)
Non-Operating Income/Expenses	-0.4	2.6	2.2	0.2	1.3	1.5	+0.6	-1.3	-0.7
Foreign exchange Gains/Losses	-0.8	1.8	1.0	-0.4	0.9	0.5	+0.4	-0.9	-0.5
Ordinary Income	27.9	15.4	43.3	29.8	16.7	46.5	+1.9 (+7%)	+1.3 (+9%)	+3.2 (+7%)
Extraordinary Income/Losses	0.8	0.0	0.8	0.0	0.0	0.0	-0.8	0.0	-0.8
Net Income ¹	20.5	11.2	31.7	22.8	12.2	35.0	+2.3 (+11%)	+1.0 (+9%)	+3.3 (+11%)
EBITDA ²	34.5	16.7	51.2	36.6	19.5	56.1	+2.1	+2.8	+4.9
EPS (¥/share)	148.78	81.49	230.27	168.45	90.65	259.10	+19.67	+9.16	+28.83
Dividend (¥/share)	70	-	70	70	-	70	0	-	0
Total amount of Dividend	9.6	-	9.6	9.4	-	9.4	-0.2	-	-0.2
OP Margin	24.0%	22.5%	23.5%	22.8%	23.5%	23.0%	-1.2pt	+1.0pt	-0.5pt
FX Rate (¥/\$)	153	152	153	146	154	149	-	-	-

1. Net Income = Profit Attributable to Owners of Parent

2. EBITDA = Operating Profit + Depreciation and amortization

3Q FY2025 Financial Summary Compared to Outlook

	(¥billion)				
	FY2025 Outlook as of Nov 2025		FY2025 Actual		vs. Outlook
	3Q	1-3Q	3Q	1-3Q	3Q
Sales	59.5	189.6	65.3	195.4	+5.8
Operating Profit	12.0	41.6	15.4	45.0	+3.4
Non-Operating Income/Expenses	-0.6	-0.4	1.3	1.5	+1.9
Foreign exchange Gains/Losses	-0.8	-1.2	0.9	0.5	+1.7
Ordinary Income	11.4	41.2	16.7	46.5	+5.3
Extraordinary Income/Losses	0.0	0.0	0.0	0.0	0.0
Net Income¹	8.3	31.1	12.2	35.0	+3.9
EBITDA²	-	-	19.5	56.1	-
EPS (¥/share)	-	-	90.65	259.10	-
Dividend (¥/share)	-	70	-	70	-
Total amount of Dividend	-	9.4	-	9.4	-
OP Margin	20.2%	21.9%	23.5%	23.0%	-
FX Rate (¥/\$)	145	146	154	149	-

1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization

Analysis of Changes in OP

(¥)

	FY2025 Actual	FY2024 Actual	YOY Change	Outlook as of Nov 2025	vs. Outlook
	15.4 billion	12.8 billion	+2.6 billion(+21%)	12.0 billion	+3.4 billion
Performance Materials	YOY Change +1.4 billion		OP increase due to sales increase in Semis Materials and Inorganic Materials		
	vs. Outlook +1.3 billion		OP increase due to sales increase in Semis Materials		
Agro	YOY Change +1.2 billion		OP increase due to sales increase in GRACIA and Fluralaner etc.		
	vs. Outlook +0.8 billion		OP increase due to sales increase in LEIMAY and GRACIA etc.		
Chemicals	YOY Change -0.2 billion		OP decrease due to sales decrease in FINEOXOCOL etc.		
	vs. Outlook in line				
Healthcare	YOY Change flat				
	vs. Outlook +0.2 billion		OP increase due to sales increase in Custom Chemicals		

3Q

	FY2025 Actual	FY2024 Actual	YOY Change
	45.0 billion	41.1 billion	+3.9 billion(+10%)
Performance Materials	YOY Change +4.3 billion		OP increase due to sales increase in Semis Materials and Inorganic Materials (+19%)
Agro	YOY Change -1.2 billion		OP decrease due to fixed cost etc. ¹ up despite sales increase in LEIMAY and ALTAIR etc. (-6%)
Chemicals	YOY Change flat		
Healthcare	YOY Change -0.6 billion		OP decrease due to sales decrease in Custom Chemicals

1. Fixed cost etc.: including inventory adjustment cost

1-3Q

Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Losses YoY Change

(¥billion)

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Interest income, dividend income	0.59	0.66	1.25	1.17	0.30	1.47	+0.58	-0.36	+0.22
Equity in earnings of affiliates	0.14	0.33	0.47	0.16	0.34	0.50	+0.02	+0.01	+0.03
Foreign exchange gains/losses ¹	-0.83	1.78	0.95	-0.45	0.90	0.45	+0.38	-0.88	-0.50
Interest expense	-0.35	-0.14	-0.49	-0.22	-0.07	-0.29	+0.13	+0.07	+0.20
Loss on disposal of non- current assets, others	0.05	0.01	0.06	-0.46	-0.14	-0.60	-0.51	-0.15	-0.66
Non-Operating Income/Expenses	-0.40	2.64	2.24	0.20	1.33	1.53	+0.60	-1.31	-0.71
Extraordinary Income	0.82	0.00	0.82	0.00	0.00	0.00	-0.82	0.00	-0.82
Extraordinary Losses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Extraordinary Income/Losses	0.82	0.00	0.82	0.00	0.00	0.00	-0.82	0.00	-0.82

1. FX Rate (¥/\$): 2024/3 151.40, 2024/9 142.82, 2024/12 158.17,
2025/3 149.53, 2025/9 148.89, 2025/12 156.54

Cash Flows

Free cash flow in 1-3Q FY2025 is ¥36.5 billion, an increase of ¥2.6 billion from 1-3Q FY2024

(¥billion)

	FY2024 Actual	FY2025 Actual	YOY Change
	1-3Q	1-3Q	
CF from operating activities	47.3	51.8	+4.5
Income before income taxes & non-controlling interests	44.2	46.5	+2.3
Extraordinary loss (income)	-0.8	0.0	+0.8
Depreciation & amortization ¹	10.1	11.2	+1.1
Income taxes paid	-11.6	-16.5	-4.9
Working capital, others	5.4	10.6	+5.2
CF from investing activities	-13.4	-15.3	-1.9
Purchase of PPE ²	-12.7	-13.2	-0.5
Purchase and sales of investment securities	-0.1	-0.1	0.0
Others	-0.6	-2.0	-1.4
Free cash flow	33.9	36.5	+2.6
CF from financing activities	-27.4	-31.5	-4.1
Payout to shareholders (dividend)	-22.7	-23.6	-0.9
Payout to shareholders (share repurchase)	-10.0	-8.3	+1.7
Borrowings	5.3	0.6	-4.7
Others	0.0	-0.2	-0.2
Effect of exchange rate change on cash & cash equivalents	-0.1	1.6	+1.7
Change in cash & cash equivalents	6.4	6.6	+0.2
Cash & cash equivalents at end of period	29.2	34.0	+4.8

1. Including amortization of goodwill 2. Including intangible assets

Balance Sheets

(¥billion)

	2024/12	2025/3	2025/12	vs. 2025/3
Current assets	205.4	210.4	208.9	-1.5
Cash	29.2	27.5	34.0	+6.5
Accounts receivable	73.0	89.1	77.0	-12.1
Inventories	90.6	80.1	84.7	+4.6
Others	12.6	13.7	13.2	-0.5
Fixed assets	124.4	120.4	131.2	+10.8
Total PPE	77.9	72.4	76.6	+4.2
Intangible assets	13.0	13.5	12.9	-0.6
Investment securities	25.4	24.4	31.1	+6.7
Others	8.1	10.1	10.6	+0.5
Total assets	329.8	330.8	340.1	+9.3

	2024/12	2025/3	2025/12	vs. 2025/3
Liabilities	101.0	94.6	94.6	0.0
Accounts payable	23.7	19.9	23.7	+3.8
Borrowings, CP & Bonds	47.7	40.5	40.9	+0.4
Others	29.6	34.2	30.0	-4.2
Net assets	228.8	236.2	245.5	+9.3
Shareholders' equity ¹	213.1	222.9	226.0	+3.1
Valuation difference on available-for-sale securities	7.7	7.0	10.4	+3.4
Foreign currency translation adjustment	3.9	1.8	4.0	+2.2
Non-controlling interests	3.2	2.9	3.7	+0.8
Remeasurements of defined benefit plans	0.9	1.6	1.4	-0.2
Total liabilities & net assets	329.8	330.8	340.1	+9.3
Equity Ratio	68.4%	70.5%	71.1%	
Net D/E Ratio²	0.09	0.06	0.03	

Breakdown of Investment Securities

	2024/12	2025/3	2025/12	vs. 2025/3
Listed shares³ (Number of stocks held, Non-consolidated basis)	16.5 (24)	15.6 (24)	20.5 (24)	+4.9 (0)
Unlisted shares	2.2	2.3	2.4	+0.1
Subsidiaries/Associate shares	6.7	6.5	8.2	+1.7
Total	25.4	24.4	31.1	+6.7
Strategic shareholdings on net assets⁴	7.4%	6.9%	8.4%	

Reference

2018/3
30.0 (55)
1.7
6.8
38.5
17.0%

1. Change in shareholders' equity +3.1 = Net Income 35.0 – Dividend and others 31.9

3. 2025/3 15.6 + Acquisition 0.0 + Sales and valuation difference +4.9 = 2025/12 20.5

4. Strategic shareholdings on net assets = strategic shareholdings (Non-consolidated basis, Listed shares + Unlisted shares) / Net assets (Consolidated basis)


2. Net D/E Ratio = (Borrowings + Bonds + CP - Cash) / Shareholders' equity

Contents


- 01
- 02
- 03
- 04

3Q FY2025 Financial Results	P3
Segment Performance	P11
ESG Topics	P31
Appendix	P36

FY2025 Outlook by Segment (¥billion)¹



Performance Materials – Recent Financial Performance^{2,3}



1. Outlook as of Nov 2025

2. FY2025- : New OP Method adopted. FY2024 Actual have been restated based on the new method (see p48).

3. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022.

Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure.

- DP Materials: 【1-3Q】 Sales YOY +1%, Sales below target
- Semis Materials: 【1-3Q】 Sales YOY +23%, Sales above target
- Inorganic Materials: 【1-3Q】 Sales YOY +9%, Sales in line with target

Main Products	YOY Change		vs. Outlook as of Nov 2025
	3Q	1-3Q	
Total Display Materials	-10%	+1%	Below
Total Semis Materials	+32%	+23%	Above
ARC®	+31%	+17%	Above
Multi layer process materials	+39%	+36%	Above
EUV materials ¹	+36%	+21%	In line
Total Inorganic Materials	+9%	+9%	In line
Total Segment	+12%	+12%	Above

1. EUV materials: Both Under Layer and Si-HM for EUV

(¥billion)

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Sales	48.6	25.6	74.2	54.4	28.6	83.0	+5.8	+3.0	+8.8
OP	14.5	8.0	22.5	17.4	9.4	26.8	+2.9	+1.4	+4.3

Fixed cost & others 【3Q】 up ¥1.1 billion 【1-3Q】 up ¥2.1 billion

Display Materials

【3Q】 Sales & OP down 【1-3Q】 Sales & OP up

Photo IPS

【3Q】 Sales flat
【1-3Q】 Sales up (large monitor up)

Rubbing IPS

【3Q】【1-3Q】 Sales down

VA

【3Q】【1-3Q】 Sales down

Semis Materials

【3Q】【1-3Q】 Sales & OP up

Mainly advanced materials up

ARC®

【3Q】【1-3Q】 Sales up

Multi layer process materials

【3Q】【1-3Q】 Sales up

EUV materials

【3Q】【1-3Q】 Sales up

3D packaging process materials

【3Q】 Sales down 【1-3Q】 Sales up

Fixed cost & others 【3Q】 up ¥1.0 billion 【1-3Q】 up ¥1.8 billion

Inorganic Materials

【3Q】【1-3Q】 Sales & OP up

【3Q】【1-3Q】 Sales up in SNOWTEX (polishing)

	FY2025 Outlook as of Nov 2025		FY2025 Actual		(¥billion) vs. Outlook
	3Q	1-3Q	3Q	1-3Q	3Q
Sales	27.4	81.8	28.6	83.0	+1.2
OP	8.1	25.5	9.4	26.8	+1.3

Display Materials

**【3Q】Sales below target
OP in line with target**

Photo IPS Sales in line with target

Rubbing IPS Sales in line with target

VA Sales below target

Semis Materials

【3Q】Sales & OP above target

Mainly advanced materials up

ARC® Sales above target

Multi layer process
materials Sales above target

EUV materials Sales in line with target

3D packaging
process materials Sales below target


Inorganic
Materials

【3Q】Sales in line with target, OP above target


Sales above target in SNOWTEX (polishing)

Sales below target in Oilfield materials

FY2025 Outlook by Segment (¥billion)¹



Agrochemicals – Recent Financial Performance^{2,3}



1. Outlook as of Nov 2025

2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method (see p48).

3. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022.

Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure.

【1-3Q】Sales YOY +14%, Sales above target

Main Products (Agro: in order of FY2024 Sales amount)	Types	YOY Change		vs. Outlook as of Nov 2025
		3Q	1-3Q	
Agro	ROUNDUP ¹	Herbicide	+29%	+5% Above
	ALTAIR	Herbicide	+43%	+49% Above
	GRACIA	Insecticide	+76%	+6% Above
	LEIMAY	Fungicide	+84%	+56% Above
	TARGA	Herbicide	-68%	+6% Below
	PERMIT	Herbicide	+31%	+18% Above
	DITHANE	Fungicide	+52%	+33% In line
	VERDAD ²	Herbicide	-	- Above
Animal Health	Fluralaner	Animal Health products	+30%	+8% Below
Total Segment³		-	+32%	+14% Above


GRACIA Sales

- Initial peak sales target of ¥10.0 billion was achieved in FY2024
- Sales target was revised upward to ¥12.5 billion in May 2025

Reference

[Agrochemicals Business Briefing](#)
(January 13, 2026)

[ROUNDUP Business Briefing](#)
(January 22, 2020)



- ROUNDUP AL for general household account for 28% of total ROUNDUP sales (1-3Q FY2025 Actual)
- VERDAD was launched in 4Q FY2024
- Total segment sales YOY include discount

(\$billion)

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Sales	39.2	14.6	53.8	42.3	19.2	61.5	+3.1	+4.6	+7.7
OP	14.4	3.8	18.2	12.0	5.0	17.0	-2.4	+1.2	-1.2

Fixed cost & others [3Q] up ¥1.3 billion : including fixed cost up ¥0.5 billion and inventory adjustment cost up ¥0.8 billion

[1-3Q] up ¥4.2 billion : including fixed cost up ¥2.1 billion

(rebound from temporary decrease in expense of ¥1.2 billion in FY2024)

and higher R&D expenses associated with new products development in FY2025)

inventory adjustment cost up ¥2.1 billion

(Increase in carryover fixed costs due to higher shipments in FY2025)

【3Q】Sales & OP up

ROUNDUP Sales up (ML: partial shipment shifted from 4Q)

LEIMAY

Sales up
(export: sales up due to increased demand in Europe)

ALTAIR Sales up
(domestic: increased demand due to a surge in rice prices)

PERMIT

Sales up
(export: sales up due to increased demand in Americas)

GRACIA Sales up (export: shipment skewed to 3Q in FY2025)

Fluralaner

Sales up
(API: sales up,
royalties: down due to decrease in certain royalty rates)

【1-3Q】Sales up, OP down

ROUNDUP Sales up (ML: volume up due to completion of distribution
inventory adjustment, partial shipment shifted from 4Q)

LEIMAY

Sales up
(export: sales up due to increased demand in Europe)

ALTAIR Sales up
(domestic: increased demand due to a surge in rice prices)

PERMIT

Sales up
(export: sales up due to increased demand in Americas)

GRACIA Sales up (domestic: sales expansion)

Fluralaner

Sales up (API: sales up due to partial shipment shifted
from FY2024, royalties: down, affected by JPY
appreciation and decrease in certain royalty rates)

(¥billion)

FY2025 Outlook as of Nov 2025		FY2025 Actual		vs. Outlook as of Nov 2025	
	3Q	1-3Q	3Q	1-3Q	3Q
Sales	16.8	59.1	19.2	61.5	+2.4
OP	4.2	16.2	5.0	17.0	+0.8

【3Q】 Sales & OP above target

ROUNDUP Sales above target (ML: partial shipment shifted from 4Q)

ALTAIR Sales above target
(domestic: increased demand due to a surge in rice prices)

GRACIA Sales above target
(export: partial shipment shifted from 4Q)

LEIMAY Sales above target
(export: sales up due to increased demand in Europe)

PERMIT Sales above target
(export: sales up due to increased demand in Americas)

Fluralaner Sales below target slightly
(API: sales above target, royalties: sales below target)

Launch	Products	Application	Product development type	Notes
Existing products	2002 ROUNDUP	Herbicide	Acquired	Acquired domestic business from Monsanto, continuing to grow
	2008 LEIMAY	Fungicide	In-house	
	2008 STARMITE	Insecticide	In-house	
	2009 PULSOR (THIFLUZAMIDE)	Fungicide	Acquired	Acquired world business from Dow
	2010 ROUNDUP AL	Herbicide	In-house	For general household shower-type herbicide market, launched ROUNDUP AL II in FY2016 and AL III in FY2017
	2011 ALTAIR	Herbicide	In-house	For paddy rice. Launched in Korea in FY2011 and in Japan in FY2012
	2013 Fluralaner	Animal health product	In-house	Started to be supplied to MAH ¹ as the API of BRAVECTO®
	2014 BRAVECTO® ²	Veterinary medical product for companion animals	-	Launched in several countries in EU in April 2014, in USA in June 2014 and in Japan in July 2015
	2017 TRANSFORM™ / EXCEED™ / VIRESCO™	Insecticide	Licensed-in	Licensed from Dow
New products · Pipeline	2018 GRACIA	Insecticide	In-house	Effective against a wide range of serious pests, having less negative impact on honeybees. Launched in Korea in FY2018, in Japan in FY2019, and in India and Indonesia in FY2021. Expanding sales countries (expected peak sales ¥12.5 billion)
	2019 QUINTEC (QUINOXYFEN)	Fungicide	Acquired	Acquired world business from Corteva. Protective fungicide highly effective in controlling powdery mildew in fruits and vegetables
	2020 DITHANE (MANCOZEB)	Fungicide	Acquired	Acquired Japan and Korea business from Corteva in December 2020. Protective fungicide with significant efficacy against various plant diseases in fruits and vegetables
	2024 VERDAD (DIMESULFAZET) (NC-653)	Herbicide	In-house	For paddy rice. Effective against resistant weeds, having excellent safety to rice (expected peak sales ¥6.0 billion)
	2027 RYZONIC (IPTRIAZOPYRID) (NC-656)	Herbicide	In-house	Our first foliar application rice herbicide with excellent efficacy against resistant grass weeds (expected peak sales ¥15.0 billion ³)
	2028 PREXIO (FENMEZODITIAZ) (NC-520)	Insecticide	Joint development	Insecticide for paddy rice co-developed with BASF. Highly effective against planthoppers (expected peak sales ¥2.5 billion including mixture products)

1. MAH: MSD Animal Health, the global animal health business unit of Merck

2. BRAVECTO®: the product name developed by MAH, containing the active substance Fluralaner

3. Expected peak sales of RYZONIC were revised upward from ¥10.0 billion to ¥15.0 billion in January 2026


Expected peak sales of new products

¥41.0 billion³

No.1 in the domestic agrochemicals sales ranking (Oct 2023- Sep 2024)


In Agrochemical sales(excluding Fluralaner), domestic sales are higher than export sales.

Export ratio of agrochemicals business (FY2024 Actual)^{1,2}




1. Sales before discount
2. Excluding Fluralaner

Distribution by Region




Expand product portfolio through sales expansion of existing products, launching in-house developed products, acquisition and introduction of pesticides

Nissan Chemical Sales Trend




Nissan Chemical Sales Distribution



- BRAVECTO® series and EXZOLT®, which contain the active pharmaceutical ingredient of Fluralaner invented by Nissan Chemical, are currently available in more than 100 countries.
- BRAVECTO®'s greatest feature is its effectiveness, which lasts up to 12 weeks (competing products last up to about 1 month)
- **Long-term supply agreement with MAH¹ for Fluralaner extended, joint R&D to create new animal health products (News release on April 11, 2025)**

I. Fluralaner



II. BRAVECTO® for external parasites (Ecto)

III. BRAVECTO® for both internal and external parasites (Endecto)

IV. EXZOLT®



I. Fluralaner

- Invented by Nissan Chemical and supplied to MAH¹ as the active pharmaceutical ingredient of BRAVECTO® and EXZOLT®
- Currently, BRAVECTO® series and EXZOLT® are available in more than 100 countries
- Compound patent
 - Fluralaner's compound patent expires in March 2025, but many countries have the patent term extension system
 - Some EU countries including UK, France, and Germany – already extended to February 2029
 - USA - extended to June 2027

II. BRAVECTO® for Ecto

- Developed and launched by MAH¹
- Veterinary medical products providing 12 weeks² of continuous protection for dogs and cats against fleas and ticks with immediate effect, nearly 3 times longer than any monthly products in the market.
- Chewable tablet for dogs launched in:
 - April 2014 EU, thereafter, USA, Japan, etc.
 - July 2020 monthly chews for puppies in USA
- Spot-on solution for dogs and cats launched in:
 - July 2016 EU, thereafter, USA, Japan, etc.
- Injectable solution for dogs (BRAVECTO® Quantum)
 - Providing 12 months³ of continuous protection
 - Launched in Australia in June 2024, and thereafter, in Europe, etc.
 - Launched in USA in August 2025

III. BRAVECTO® for Endecto

- BRAVECTO® Plus
 - spot-on solution for cats
 - Launched in EU in July 2018, thereafter, USA, Japan, etc.
- BRAVECTO® TriUNO
 - Three-in-one chewable tablet for dogs
 - Providing 1 month of continuous protection
 - Approved in EU countries and Latin America in October 2024


IV. EXZOLT®

- Poultry medicine against red mite (administered via drinking water)
 - Launched in EU in 2017, thereafter, Korea, Middle East and Japan.
- Cattle medicine
 - Launched in Brazil in 2022, thereafter Mexico
- Sheep medicine
 - Launched in Australia and New Zealand in 2023

Nissan Chemical's Revenues are Consisted from Following Two Factors

- Sales of Fluralaner to MAH¹ as API² of BRAVECTO® and EXZOLT® products
- Running royalties received from MAH

FY2024 - FY2025 Quarterly Sales (including royalties)



Our Fluralaner sales tend to be larger in 1H due to MAH's BRAVECTO® and EXZOLT® sales trend.


BRAVECTO® series R&D

MAH is developing new internal and external parasiticides for pets with Fluralaner as the API, and expanding the number of the countries for existing products.

1. MAH: MSD Animal Health, the global animal health business unit of Merck

2. API: Active Pharmaceutical Ingredient


FY2021 - FY2025 Sales Trend (including royalties)




- Large sales increase in FY2022 due to shipments shifted from FY2021 to FY2022 and JPY depreciation. Actual exchange rate is ¥136/\$.
- Actual exchange rate for FY2023 is ¥145/\$.
- Actual exchange rate for FY2024 is ¥153/\$.
- FY2025 outlook is +12% YOY, with API sales increase by +47% due to shipments shifted from FY2024.

Assumed exchange rate for 2H FY2025 is ¥145/\$.

FY2025 Outlook by Segment (¥billion)¹



Chemicals – Recent Financial Performance^{2,3}



1. Outlook as of Nov 2025

2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method (see p48).

3. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022.

Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure

YOY Change

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Sales	17.9	10.2	28.1	18.8	10.1	28.9	+0.9	-0.1	+0.8
Fine Chemicals	6.3	3.4	9.7	6.8	3.2	10.0	+0.5	-0.2	+0.3
Basic Chemicals	11.6	6.8	18.4	12.0	6.9	18.9	+0.4	+0.1	+0.5
OP	-0.3	0.5	0.2	-0.1	0.3	0.2	+0.2	-0.2	0.0

1. FY2024 Actual have been restated based on the new method (see p48)

【3Q】 Sales & OP down

In Fine Chemicals, OP down due to sales down in FINEOXOCOL

In Basic Chemicals, OP down due to fixed costs & others up despite sales up in high purity sulfuric acid (demand increase for semiconductors)

【1-3Q】 Sales up, OP flat

In Fine Chemicals, OP up due to sales up in FINEOXOCOL and environmental related products

In Basic Chemicals, OP down due to fixed costs & others up despite sales up in high purity sulfuric acid (demand increase for semiconductors) and urea/AdBlue®

Compared to Outlook

	FY2025 Outlook as of Nov 2025		FY2025 Actual		vs. Outlook
	3Q	1-3Q	3Q	1-3Q	
Sales	10.3	29.1	10.1	28.9	-0.2
Fine Chemicals	3.1	9.9	3.2	10.0	+0.1
Basic Chemicals	7.2	19.2	6.9	18.9	-0.3
OP	0.3	0.2	0.3	0.2	0.0


【3Q】 Sales below target, OP in line with target

In Fine Chemicals, sales above target in TEPI


In Basic Chemicals, sales below target in high purity sulfuric acid and nitric acid products

Flow Chart of Selected Basic and Fine Chemicals Products (No change from the May 2025 announcement)


- Core products are ammonia related products and sulfuric acid related products
- FY2024 ammonia domestic production capacity share 11%
- Focus on high value-added products, such as high purity sulfuric acid, instead of pursuing scale



FY2025 Outlook by Segment (¥billion)¹



Healthcare – Recent Financial Performance^{2,3}



1. Outlook as of Nov 2025

2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method (see p48).

3. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022.

Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure.

| YOY Change

(¥billion)

	FY2024 Actual			FY2025 Actual			YOY Change		
	1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Sales	3.3	1.1	4.4	2.8	1.2	4.0	-0.5	+0.1	-0.4
OP	1.3	0.4	1.7	0.7	0.4	1.1	-0.6	0.0	-0.6

1. FY2024 Actual have been restated based on the new method (see p48).

[3Q] Sales up, OP flat

[1-3Q] Sales & OP down

Sales up in LIVALO export, Sales down in Custom Chemicals

| Compared to Outlook

(¥billion)

	FY2025 Outlook as of Nov 2025		FY2025 Actual		vs. Outlook
	3Q	1-3Q	3Q	1-3Q	3Q
Sales	1.0	3.8	1.2	4.0	+0.2
OP	0.2	0.9	0.4	1.1	+0.2

[3Q] Sales & OP above target

Sales above target in Custom Chemicals

3Q FY2025 Financial Results YOY Change by Segment

(¥billion)

		FY2024 Actual			FY2025 Actual			YOY Change		
		1H	3Q	1-3Q	1H	3Q	1-3Q	1H	3Q	1-3Q
Performance Materials	Sales	48.6	25.6	74.2	54.4	28.6	83.0	+5.8 (+12%)	+3.0 (+12%)	+8.8 (+12%)
	OP	14.5	8.0	22.5	17.4	9.4	26.8	+2.9 (+20%)	+1.4 (+18%)	+4.3 (+19%)
Agrochemicals	Sales	39.2	14.6	53.8	42.3	19.2	61.5	+3.1 (+8%)	+4.6 (+32%)	+7.7 (+14%)
	OP	14.4	3.8	18.2	12.0	5.0	17.0	-2.4 (-17%)	+1.2 (+34%)	-1.2 (-6%)
Chemicals	Sales	17.9	10.2	28.1	18.8	10.1	28.9	+0.9 (+5%)	-0.1 (-1%)	+0.8 (+3%)
	OP	-0.3	0.5	0.2	-0.1	0.3	0.2	+0.2 (-)	-0.2 (-33%)	0.0 (+16%)
Healthcare	Sales	3.3	1.1	4.4	2.8	1.2	4.0	-0.5 (-14%)	+0.1 (+1%)	-0.4 (-10%)
	OP	1.3	0.4	1.7	0.7	0.4	1.1	-0.6 (-46%)	0.0 (0%)	-0.6 (-36%)
Trading, Others, Adjustment	Sales	9.2	5.1	14.3	11.8	6.2	18.0	+2.6	+1.1	+3.7
	OP	-1.6	0.1	-1.5	-0.4	0.3	-0.1	+1.2	+0.2	+1.4
Total	Sales	118.2	56.6	174.8	130.1	65.3	195.4	+11.9 (+10%)	+8.7 (+15%)	+20.6 (+12%)
	OP	28.3	12.8	41.1	29.6	15.4	45.0	+1.3 (+4%)	+2.6 (+21%)	+3.9 (+10%)

1. Including inter-segment sales/transfers

2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech (added as consolidated subsidiaries from FY2024), Nihon Hiryo, and others

Adjustment: Planning & Development Division and others (see p46, p47 for breakdown)

3. FY2024 Actual have been restated based on the new method (see p48)

3Q FY2025 Financial Results Compared to Outlook by Segment

		FY2025 Outlook as of Nov 2025		FY2025 Actual		(¥billion)
		3Q	1-3Q	3Q	1-3Q	vs. Outlook
Performance Materials	Sales	27.4	81.8	28.6	83.0	+1.2
	OP	8.1	25.5	9.4	26.8	+1.3
Agrochemicals	Sales	16.8	59.1	19.2	61.5	+2.4
	OP	4.2	16.2	5.0	17.0	+0.8
Chemicals	Sales	10.3	29.1	10.1	28.9	-0.2
	OP	0.3	0.2	0.3	0.2	0.0
Healthcare	Sales	1.0	3.8	1.2	4.0	+0.2
	OP	0.2	0.9	0.4	1.1	+0.2
Trading, Others, Adjustment	Sales	4.0	15.8	6.2	18.0	+2.2
	OP	-0.8	-1.2	0.3	-0.1	+1.1
Total	Sales	59.5	189.6	65.3	195.4	+5.8
	OP	12.0	41.6	15.4	45.0	+3.4

1. Including inter-segment sales/transfers

2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech (added as consolidated subsidiaries from FY2024), Nihon Hiryo ,and others, Adjustment: Planning & Development Division and others (see p46, p47 for breakdown)

Contents

- 01
- 02
- 03
- 04

3Q FY2025 Financial Results	P3
Segment Performance	P11
ESG Topics	P31
Appendix	P36

E
(Environment)
S
(Social)

April 2021	Announced its Diversity Statement and Diversity Vision
May 2022	Decided to work on realization of carbon neutrality by 2050 Established new long-term target for reducing greenhouse gas (GHG) emissions(see p35)
June 2022	Reduced GHG emissions by melamine production stop (26,000 tons, equivalent to about 7% of FY2018)
June 2022	Established Climate Change Committee
October 2025	Published " Integrated Report 2025 "

G
(Governance)

April 2019	Established Nomination and Remuneration Advisory Committee as an optional advisory body of the Board of Directors
June 2019	Introduced a performance-linked stock compensation plan called a Board Benefit Trust for Board of Directors, etc.
June 2022	Announced incorporating ESG indicators into the officers' remuneration system (65% base remuneration, 28% performance-related remuneration, 7% remuneration in stock. Out of the 28% performance-related remuneration, 90% is profit-linked and 10% is ESG-linked.)
June 2025	Two female Outside Directors appointed (re-elected), as a result, the Board of Directors includes 4 Outside Directors out of 10 One female Outside Audit & Supervisory Board Member appointed (newly elected), as a result, the Board of Audit & Supervisory includes 3 Outside Directors out of 4
December 2025	Updated and disclosed " Corporate Governance Report "

ESG Index and Third-party Recognition

Dow Jones Sustainability Asia Pacific Index

- December 2024
Selected as a constituent
for 7 consecutive years



FTSE

- June 2025: Selected as a constituent of FTSE4Good Index Series, FTSE Blossom Japan Index for 6 consecutive years
- June 2025: Selected as a constituent of FTSE Blossom Japan Sector Relative Index for 4 consecutive years

1. FTSE Russell confirms that Nissan Chemical has been independently assessed according to the index criteria, and has satisfied the requirements to become a constituent of the FTSE Blossom Japan Sector Relative Index. The FTSE Blossom Japan Sector Relative Index is used by a wide variety of market participants to create and assess responsible investment funds and other products.



Certified Health & Productivity Management Organization (White 500)

- March 2025: Acquired for 9 consecutive years



Participation in External Initiatives



S&P/JPX Carbon Efficient Index

- June 2025
Selected as a constituent
for 7 consecutive years



MSCI

- May 2025: Upgraded from A to AA (MSCI ESG Rating)
- June 2025: Selected as a constituent of MSCI Nihonkabu ESG Select Leaders Index for 2 consecutive years

2025 CONSTITUENT MSCI NIHONKABU ESG SELECT LEADERS INDEX

2. THE INCLUSION OF NISSAN CHEMICAL CORPORATION IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF NISSAN CHEMICAL CORPORATION BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.

Morningstar

- December 2025: Selected as a constituent of Japan ex-REIT Gender Diversity Tilt Index for 3 consecutive years

CDP

- January 2026:
Selected as A List for CDP Water Security



“Childcare Support Company” Kurumin

- January 2023
Acquired for 2 consecutive years



Specified materiality that we should engage to realize corporate image of 2027.
Aim to have sustainable growth with society by promoting initiatives.

»»»1

Provision of New Value for Helping to Enrich People's Lives

► Nissan Chemical Sustainable Agenda¹

Rate of total sales of products and services that contribute to solving social issues in consolidated net sales

60% or more

(revised upward from maintain at least 55%)

1. A plan to pursue "what we can do for the future of the globe and human" by providing products and services that contribute to solving social issues

»»»2

Strengthening of Nissan Chemical's Business Base

► Personnel retention and trainings

Positive response rate in survey of employee attitude

65% or more

► Promote Diversity

Proportion of female researchers

18% or more

»»»3

Continuous Improvement of Responsible Care Activities

► GHG Emission Target Reduced by **30% or more** compared to FY2018


Our Materiality

Strengthening of Corporate Governance, Risk Management and Compliance

Reduction of GHG Emissions

- Focus on improving production technology and adopting renewable energy etc., in addition to conventional efforts, to achieve carbon neutrality by 2050
- GHG emissions target for FY2027: Reduce by at least 30% compared to FY2018 (SCOPE1+2, non-consolidated basis)

(Thousands of tons of -CO₂e)



Comparison of GHG emissions with general chemical manufacturers

(Thousands of tons -CO₂e)

FY	2019	2020	2021	2022	2023	2024
Nissan Chemical (consolidated basis)	346	337	364	346	305	315
Average of 4 major general chemical manufacturers (consolidated basis)	9,275	8,928	9,226	8,390	7,803	7,691

Initiatives in Medium-Term Plan Vista2027 (FY2022-2027)

- Zero N₂O emissions from nitric acid plants
(Planned investment of ¥830 million, variable cost of ¥70 million/year)
- Melamine production shutdown
- Converting fuels at Onoda Plant
- Promoting reduction of GHG emissions through full-scale introduction of ICP
- Reduction of CFC equipment
- Upgrade to energy-efficient equipment

Contents

01
02
03
04

3Q FY2025 Financial Results	P3
Segment Performance	P11
ESG Topics	P31
Appendix	P36

Medium-Term Plan Vista2027 Stage II (FY2025-2027)

(announced in May 2025)

PL

	FY2024 Actual	FY2025 Outlook as of Nov 2025	FY2027 Mid-Term Plan	(¥billion) FY2027 previous Mid-Term Plan
Sales	251.4	277.2	293.0	285.0
Operating Profit	56.8	59.0	65.0	67.0
Ordinary Income	58.0	59.0	65.5	68.0
Net Income ¹	43.0	44.0	48.0	50.0
EBITDA ²	71.2	74.9	83.4	-
EPS(¥/share)	313.26	328.22	366.28	371.67
Equity Ratio	70.5%	-	71.9%	-
Net D/E Ratio ³	0.06	-	0.05	-

(Financial Target)	FY2024 Actual	FY2025~FY2027 Mid-Term Plan	FY2027 previous Mid-Term Plan
OP Margin	22.6%	20% or more	20% or more
ROE	18.7%	18% or more	18% or more
Dividend Payout Ratio	55.5%	55% or more	55% or more
Total Payout Ratio	82.0%	75% or more	75% or more

FX Rate (¥/\$)	153	FY2025:146 FY2026~2027:140
----------------	-----	-------------------------------

Segment

		FY2024 Actual	FY2025 Outlook as of Nov 2025	FY2027 Mid-Term Plan	(¥billion) FY2027 previous Mid-Term Plan
Performance Materials	Sales	100.1	109.7	122.4	117.2
	OP	29.3	32.1	34.2	38.0
Agrochemicals	Sales	86.2	95.9	97.5	82.3
	OP	25.9	26.0	25.9	21.0
Chemicals	Sales	37.8	39.6	43.7	40.1
	OP	0.4	0.8	2.4	3.9
Healthcare	Sales	6.0	5.3	6.4	11.5
	OP	1.9	1.5	2.4	4.3
Trading, Others, Adjustment	Sales	21.3	21.7	23.0	33.9
	OP	-0.7	-1.4	0.1	-0.2
Planning and Development ⁴	Sales	0.3	0.1	1.1	4.4
	OP	-4.9	-5.6	-5.0	-4.7
Total	Sales	251.4	272.2	293.0	285.0
	OP	56.8	59.0	65.0	67.0


1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization

3. Net D/E Ratio = (Borrowings + Bonds + CP - Cash) / Shareholders' equity 4. The figures of Planning and Development Division are internal figures of Trading, Others, Adjustment

5. The figures in Medium-Term Plan don't include the impact of future strategic investments (M&A)

6. FY2025- : New OP method adopted FY2024 Actual have been restated based on the new method (see p48)


- Position ROE as the most important financial indicator for a long time
- Medium-Term Plan FY2025-2027 Target: 18% or more
- FY2024 Actual: 18.7%



1. as of Nov 2025


Shareholders Return Policy - Total Payout Ratio

- Medium-Term Plan FY2025-2027 Target: 75% or more
- FY2024 Actual: 82.0%



Shareholders Return Policy – Dividend Payout Ratio

- Increase Dividend Payout Ratio Target to 55% from 45% in Medium-Term Plan (announced in May 2022)
- Current Medium-Term Plan (FY2025-2027) target: 55% or more
- Stable and continuous dividend policy
- Maintained Dividend at the same amount (¥164/share) despite FY2023 Profit down from FY2022
- Dividend for FY2024 (¥174/share), FY2025 Outlook (¥180/share), increase for 2 consecutive years



Shareholders Return Policy - Share Repurchase

- Started share repurchase in FY2006 only to enhance ROE
- Repurchased ¥135.0 billion, 50.10 million shares (26.7% of shares issued) in total from FY2006 to FY2024
- Cancelled all repurchased shares. Continue to strengthen shareholders return through share repurchase
- Completed a ¥1.5 billion share repurchase in April 2025, completed a ¥9.0 billion share repurchase until February 2026 announced in May 2025 (¥10.5 billion in total)

FY2006 - 2024 Shareholders Return (no share repurchase in FY2009 and FY2011)

Fiscal Year	2006	2007	2008	2010	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Total
Shares purchased (thousand shares) ¹	3,500	3,399	7,355	2,167	6,372	3,263	2,764	3,333	2,621	2,292	1,682	2,138	1,829	2,033	1,356	1,665	2,335	50,104
Purchase costs (¥billion) ¹	4.7	5.0	8.0	2.8	5.0	5.0	6.0	9.0	9.0	9.0	9.0	10.0	10.0	12.0	9.0	10.0	11.5	135.0
Shares cancelled (thousand shares)	3,000	3,635	7,000	3,000	6,000	4,000	3,000	2,000	2,000	3,000	2,000	3,000	1,000	2,000	1,700	2,500	2,000	50,835
Shares issued at FY end (million shares)	185	181	174	171	165	161	158	156	154	151	149	146	145	143	141	139	137	-
Treasury shares at FY end (thousand shares) ²	1,367	1,233	1,660	885	1,258	522	287	1,621	2,242	1,535	1,218	523	1,352	1,384	1,029	187	518	-
Total payout ratio(%) (dividend + share repurchase)	60	56	118	53	67	59	64	71	70	71	72	75	75	76	78	86	82	-

FY2020 - 2025 Share Repurchase and Cancel Program

Fiscal Year	2020			2021			2022			2023			2024			2025
	1H	2H	Total	1H	2H	Total	1H	2H	Total	1H	2H	Total	1H	2H	Total	Total
Shares purchased (thousand shares) ¹	1,334	495	1,829	1,262	771	2,033	683	673	1,356	805	860	1,665	1,061	1,274	2,335	2,865
Purchase costs (¥billion) ¹	7.0	3.0	10.0	7.0	5.0	12.0	5.0	4.0	9.0	5.0	5.0	10.0	5.0	6.5	11.5	10.5
Shares cancelled (thousand shares) ³	1,000	0	1,000	2,000	0	2,000	1,700	0	1,700	1,500	1,000	2,500	1,000	1,000	2,000	1,000

1. Excluding share acquisitions for performance-based compensation 2. Including share acquisitions for performance-based compensation


3. The Date of Cancellation in FY2025 is November 10

Cash Management Policy (Non-consolidated basis)

Level of Target Cash Balance = Minimum required level + 1/3 of annual scheduled long-term borrowings repayment
+ 1/3 of short-term borrowings outstanding + Contingent risk reserves

R&D Expenses Trend

- R&D expenses increased in Performance Materials, especially Semis, and Agrochemicals
- Maintain about 7-9% R&D expenses/sales in recent years



2. A change in the calculation method for partial expenses of Planning & Development Division was implemented in FY2025, FY2024 Actual was restated


- Achieve high OP margin despite aggressive investment in R&D
- About 40% of professional staff engaged in R&D

R&D Expenses by Segment


Segments	FY2024 Actual				
	Sales (\$billion)	OP (\$billion)	OP Margin	R&D expenses (\$billion)	R&D Expenses/Sales
Performance Materials	100.1	29.3	29.3%	8.3	8.3%
Agrochemicals	86.2	25.9	30.0%	4.5	5.2%
Others ¹	-	-	-	6.3	-
Total (including Others¹)	251.4	56.8	22.6%	19.1	7.6%

1. Including Planning and Development Div. , Chemicals and Healthcare

Professional Staff Distribution



Researchers



2. The staff number indicated is round number

Long-term Financial Performance Trend

	(\$billion)																				
	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025E	
Sales	174.4	169.2	160.2	149.0	154.2	148.6	153.8	163.7	171.2	176.9	180.3	193.4	204.9	206.8	209.1	208.0	228.1	226.7	251.4	272.2	
Operating Profit	20.8	24.8	17.4	19.2	19.8	15.5	19.5	22.2	25.3	28.6	31.4	35.0	37.1	38.6	42.5	51.0	52.3	48.2	56.8	59.0	
Ordinary Income	21.2	24.4	16.9	19.2	19.4	15.9	20.5	23.7	26.4	29.5	31.7	36.2	39.1	40.0	43.9	53.7	55.8	51.6	58.0	59.0	
Net Income	14.0	15.5	10.1	12.8	13.0	11.0	13.9	16.7	18.2	22.4	24.0	27.1	29.4	30.8	33.5	38.8	41.1	38.0	43.0	44.0	
EBITDA	30.5	34.5	27.6	30.1	30.3	25.9	29.1	30.8	33.8	38.3	40.3	45.5	48.0	49.2	53.0	61.2	63.3	62.0	71.2	74.9	
OP Margin	12.0%	14.6%	10.9%	12.8%	12.9%	10.4%	12.7%	13.6%	14.8%	16.2%	17.4%	18.1%	18.1%	18.7%	20.3%	24.5%	22.9%	21.3%	22.6%	21.7%	
ROE	14.7%	15.6%	10.3%	12.6%	11.9%	9.5%	11.4%	12.7%	12.7%	14.6%	15.1%	16.1%	16.6%	16.9%	17.5%	19.2%	19.4%	17.1%	18.7%	18.5%	
EPS (\$/share)	75.43	85.15	57.26	74.00	75.94	64.52	83.74	102.11	113.99	143.37	156.97	180.30	197.67	210.09	231.73	271.88	291.36	272.82	313.26	328.22	
Dividend (\$/share)	20	20	22	24	24	24	26	30	36	44	52	68	82	90	104	122	164	164	174	180	
Dividend Payout Ratio	26.5%	23.5%	38.4%	32.4%	31.6%	37.2%	31.0%	29.4%	31.6%	30.7%	33.1%	37.7%	41.5%	42.8%	44.9%	44.9%	56.3%	60.1%	55.5%	54.8%	
Share Repurchase	4.7	5.0	8.0	-	2.8	-	5.0	5.0	6.0	9.0	9.0	9.0	9.0	10.0	10.0	12.0	9.0	10.0	11.5	-	
Total Assets	177.3	172.7	172.3	181.4	183.4	190.1	199.2	208.0	223.9	228.2	231.7	246.0	247.0	249.5	265.5	279.7	298.7	323.5	330.8	-	
Net Assets	99.3	101.2	96.8	107.7	112.4	119.6	126.7	137.8	151.3	156.9	163.7	176.4	182.1	185.5	200.6	208.0	221.5	230.9	236.2	-	
Cash	11.0	7.6	9.7	14.8	21.1	27.9	31.9	30.8	31.3	35.3	35.7	37.7	36.2	30.6	32.4	34.7	29.6	22.7	27.5	-	
Liabilities with Interest	32.4	34.4	45.5	42.1	39.9	38.9	38.1	36.1	35.1	33.1	30.8	28.6	26.6	24.6	22.7	22.7	27.3	41.0	40.5	-	
Equity Ratio	55.3%	58.0%	55.5%	58.7%	60.7%	62.4%	63.0%	65.7%	66.9%	68.1%	69.9%	71.0%	73.0%	73.7%	74.9%	73.6%	73.1%	70.3%	70.5%	-	
Capex	7.7	13.8	10.7	14.4	8.7	8.9	8.1	9.1	8.7	9.5	13.5	14.4	9.9	15.5	14.3	12.4	19.4	20.2	17.6	21.5	
Depreciation	9.7	9.7	10.2	11.0	10.4	10.5	9.5	8.5	8.5	9.7	8.9	10.5	10.9	10.5	10.4	10.2	11.0	13.8	14.4	15.9	
R&D Expenses	9.9	12.5	13.7	13.1	12.6	13.6	13.7	14.2	15.0	15.8	16.1	17.2	17.8	17.2	16.5	16.0	16.8	17.3	19.1	22.1	
R&D Expenses/Sales	5.7%	7.4%	8.6%	8.8%	8.2%	9.2%	8.9%	8.7%	8.7%	8.9%	8.9%	8.9%	8.7%	8.7%	8.3%	7.9%	7.7%	7.4%	7.6%	8.1%	

1. FY2021- : Including effects of changes in accounting policies

2. FY2024- : R&D expenses include some costs of the Planning & Development division

3. Capex: Cash flows basis

4. FY2025E: Outlook as of Nov 2025.

Sales and OP Trend by Segment

Sales (A)	(¥billion)												
	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025E
Performance Materials	42.8	49.4	51.8	52.8	58.8	63.0	65.5	71.6	81.7	82.6	84.6	100.1	109.7
Agrochemicals	39.1	45.7	47.5	52.0	58.1	62.7	64.0	63.8	65.8	81.6	82.1	86.2	95.9
Chemicals	35.5	34.3	34.3	34.8	34.9	35.7	34.3	31.9	37.6	39.0	35.6	37.8	39.6
Healthcare	11.6	8.8	8.7	8.0	7.5	7.0	7.0	6.7	6.6	6.7	6.3	6.0	5.3
Trading	50.7	54.4	55.6	55.2	59.5	67.9	67.9	69.8	80.4	99.1	103.8	117.2	121.6
Others	21.4	20.9	20.9	24.0	21.5	24.6	22.4	23.8	23.6	26.4	30.1	29.2	31.8
Adjustment	-37.4	-42.3	-41.9	-46.5	-46.9	-56.0	-54.3	-58.5	-87.7	-107.3	-115.8	-125.1	-133.7
Total	163.7	171.2	176.9	180.3	193.4	204.9	206.8	209.1	208.0	228.1	226.7	251.4	272.2
OP (B)													
	8.8	12.0	12.0	12.5	14.2	15.0	17.0	22.4	27.6	25.4	22.5	29.3	32.1
Performance Materials	6.2	9.2	10.8	13.2	16.4	18.4	19.3	18.2	18.1	23.1	23.4	25.9	26.0
Agrochemicals	1.9	1.9	3.9	3.8	3.4	3.0	1.3	1.5	3.8	1.4	0.0	0.4	0.8
Chemicals	4.9	2.3	2.0	1.7	1.2	1.0	0.9	0.4	2.8	3.0	2.8	1.9	1.5
Healthcare	1.5	1.7	1.8	1.7	1.8	2.0	2.1	2.5	2.9	3.7	3.7	4.1	3.6
Trading	0.8	0.6	0.5	1.0	0.6	0.9	0.7	0.8	0.7	0.9	0.6	0.6	1.5
Others	-1.9	-2.4	-2.4	-2.5	-2.6	-3.2	-2.7	-3.3	-4.9	-5.2	-4.8	-5.4	-6.5
Total	22.2	25.3	28.6	31.4	35.0	37.1	38.6	42.5	51.0	52.3	48.2	56.8	59.0
OP Margin (B)/(A)													
	20.6%	24.3%	23.2%	23.7%	24.1%	23.8%	26.0%	31.3%	33.8%	30.8%	26.6%	29.3%	29.3%
Performance Materials	15.9%	20.1%	22.7%	25.4%	28.2%	29.3%	30.2%	28.5%	27.5%	28.3%	28.5%	30.0%	27.1%
Agrochemicals	5.4%	5.5%	11.4%	10.9%	9.7%	8.4%	3.8%	4.7%	10.1%	3.6%	0.1%	1.1%	2.0%
Chemicals	42.2%	26.1%	23.0%	21.3%	16.0%	14.3%	12.9%	6.0%	42.4%	44.8%	44.4%	31.7%	28.3%
Healthcare	3.0%	3.1%	3.2%	3.1%	3.0%	2.9%	3.1%	3.6%	3.6%	3.7%	3.6%	3.5%	3.0%
Trading	3.7%	2.9%	2.4%	4.2%	2.8%	3.7%	3.1%	3.4%	3.0%	3.4%	2.0%	2.1%	4.7%
Others	13.6%	14.8%	16.2%	17.4%	18.1%	18.1%	18.7%	20.3%	24.5%	22.9%	21.3%	22.6%	21.7%
Segment Assets (FY2024)(D)													
	65.9	115.2	33.5	8.5	44.7	20.6	42.4	330.8					
ROA(FY2024)(B)/(D)													
	44.5%	22.5%	1.2%	22.4%	9.2%	2.9%	17.2%						

1. Including inter-segment sales/transfers

3. FY2021: Including Sales decrease due to changes in accounting policies

4. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech (Added as a consolidated subsidiary from FY2024), Nihon Hiryo

Adjustment: Planning & Development Division and others

6. Organizational changes in Healthcare and Planning & Development division were implemented in April 2022.

Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure.

7. FY2025E: Outlook as of Nov 2025

2. FY2019- : Consolidation items (such as unrealized gain on inventories) were included in each segment until FY2018, but are included in "Adjustment" from FY2019

5. FY2025- : New OP method adopted

FY2024 Actual have been restated based on the new method (see p48)

Quarterly Sales Trend by Segment (FY2022 - 3Q FY2025)

(¥billion)

	FY2022 Actual					FY2023 Actual					FY2024 Actual					FY2025 Actual			FY2025 Outlook as of Nov 2025	
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	3Q	4Q
	Performance Materials	21.8	20.2	20.6	20.0	82.6	20.8	19.7	21.4	22.7	84.6	23.5	25.1	25.6	25.9	100.1	25.9	28.5	28.6	27.4
Agrochemicals	19.7	16.0	13.1	32.8	81.6	18.8	16.5	13.2	33.6	82.1	20.4	18.8	14.6	32.4	86.2	26.6	15.7	19.2	16.8	36.8
Chemicals	10.4	9.4	10.1	9.1	39.0	9.1	8.8	9.6	8.1	35.6	8.9	9.0	10.2	9.7	37.8	9.3	9.5	10.1	10.3	10.5
Fine Chemicals	4.2	3.5	3.3	2.8	13.8	3.0	3.0	3.0	2.6	11.6	3.1	3.2	3.4	3.2	12.9	3.4	3.4	3.2	3.1	3.5
Basic Chemicals	6.2	5.9	6.8	6.3	25.2	6.1	5.8	6.6	5.5	24.0	5.8	5.8	6.8	6.5	24.9	5.9	6.1	6.9	7.2	7.0
Healthcare	1.7	1.5	1.6	1.9	6.7	2.0	1.5	1.3	1.5	6.3	1.5	1.8	1.1	1.6	6.0	1.6	1.2	1.2	1.0	1.5
Trading	23.7	24.0	27.0	24.4	99.1	24.3	24.5	28.3	26.7	103.8	27.5	28.8	30.8	30.1	117.2	30.0	28.8	35.7	31.1	31.7
Others	6.5	5.9	6.7	7.3	26.4	6.4	5.9	6.0	11.8	30.1	6.3	5.7	8.8	8.4	29.2	7.9	6.9	7.7	7.5	9.5
Adjustment	-25.5	-25.8	-29.4	-26.6	107.3	-26.5	-26.1	-30.2	-33.0	-115.8	-29.4	-29.7	-34.5	-31.5	-125.1	-31.4	-30.4	-37.2	-34.6	-35.3
Total	58.3	51.2	49.7	68.9	228.1	54.9	50.8	49.6	71.4	226.7	58.7	59.5	56.6	76.6	251.4	69.9	60.2	65.3	59.5	82.6

1. Including inter-segment sales/transfers

2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay,

Nippon Polytech (Added as a consolidated subsidiary from FY2024), Nihon Hiryo

Adjustment: Planning & Development Division and others

Quarterly OP Trend by Segment (FY2022 - 3Q FY2025)

(¥billion)

	FY2022 Actual					FY2023 Actual					FY2024 Actual					FY2025 Actual			FY2025 Outlook as of Nov 2025	
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	3Q	4Q
	Performance Materials	6.0	6.9	4.6	25.4	6.5	4.6	6.3	5.1	22.5	7.1	7.4	8.0	6.8	29.3	8.2	9.2	9.4	8.1	6.6
Agrochemicals	6.8	5.3	3.1	7.9	23.1	6.6	5.0	2.9	8.9	23.4	7.0	7.4	3.8	7.7	25.9	8.6	3.4	5.0	4.2	9.8
Chemicals	1.7	-0.6	0.4	-0.1	1.4	0.9	-1.0	0.4	-0.3	0.0	0.7	-1.0	0.5	0.2	0.4	0.7	-0.8	0.3	0.3	0.6
Healthcare	0.8	0.7	0.6	0.9	3.0	1.1	0.7	0.5	0.5	2.8	0.6	0.7	0.4	0.2	1.9	0.5	0.2	0.4	0.2	0.6
Trading	1.0	0.9	1.0	0.8	3.7	0.9	0.9	1.0	0.9	3.7	1.0	1.0	1.1	1.0	4.1	1.1	0.9	0.9	0.8	0.8
Others	0.1	0.0	0.2	0.6	0.9	0.2	0.0	-0.3	0.7	0.6	0.1	-0.1	0.1	0.5	0.6	0.5	0.3	0.2	0.0	0.7
Adjustment	-1.0	-1.4	-1.6	-1.2	-5.2	-1.2	-1.1	-1.5	-1.0	-4.8	-2.1	-1.5	-1.1	-0.7	-5.4	-1.5	-1.7	-0.8	-1.6	-1.7
Total	17.3	10.9	10.6	13.5	52.3	15.0	9.1	9.3	14.8	48.2	14.4	13.9	12.8	15.7	56.8	18.1	11.5	15.4	12.0	17.4

1. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech (Added as a consolidated subsidiary from FY2024), Nihon Hiryo

Adjustment: Planning & Development Division and others

2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method (see p48).

Changes in calculation methods of OP by segment

- From FY2025, OP by segment is calculated using a new method
- In the new method, some costs and others of DX and the Planning & Development division, which were previously allocated to each segment, are excluded from the segments and included in “Adjustment”
- The FY2024 Actual have been restated based on the new method, and the impact of this change is outlined below

(¥billion)

	FY2024 Actual (old method basis)					FY2024 Actual (new method basis)					Change				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Performance Materials	7.0	7.4	7.9	6.7	29.0	7.1	7.4	8.0	6.8	29.3	+0.1	0.0	+0.1	+0.1	+0.3
Agrochemicals	6.9	7.3	3.7	7.7	25.6	7.0	7.4	3.8	7.7	25.9	+0.1	+0.1	+0.1	0.0	+0.3
Chemicals	0.7	-1.1	0.5	0.1	0.2	0.7	-1.0	0.5	0.2	0.4	0.0	+0.1	0.0	+0.1	+0.2
Healthcare	0.6	0.7	0.3	0.3	1.9	0.6	0.7	0.4	0.2	1.9	0.0	0.0	+0.1	-0.1	0.0
Trading	1.0	1.0	1.1	1.0	4.1	1.0	1.0	1.1	1.0	4.1	0.0	0.0	0.0	0.0	0.0
Others	0.1	-0.1	0.1	0.5	0.6	0.1	-0.1	0.1	0.5	0.6	0.0	0.0	0.0	0.0	0.0
Adjustment	-1.9	-1.3	-0.8	-0.6	-4.6	-2.1	-1.5	-1.1	-0.7	-5.4	-0.2	-0.2	-0.3	-0.1	-0.8
Total	14.4	13.9	12.8	15.7	56.8	14.4	13.9	12.8	15.7	56.8	0.0	0.0	0.0	0.0	0.0

1. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech (Added as a consolidated subsidiary from FY2024), Nihon Hiryo
Adjustment: Planning & Development Division and others

Main Products by Segment

Segment	Products		Main Applications
Performance Materials	Display Materials	SUNEVER	LCD alignment coating
		(Main Mode) VA (Vertical Alignment)	TV
		IPS (In-Plane Switching)	Smartphone, Tablet, PC, Monitor, Automobile
	Semis Materials	ARC®(ArF, KrF)	bottom anti-reflective coating for semiconductors
		OptiStack®	multi layer process material for semiconductors (Si-HM/SOC)
		EUV materials	EUV process materials (Under Layer/Si-HM)
		3D packaging process materials	temporary adhesive materials
	Inorganic Materials	SNOWTEX	water dispersed colloidal silica sol for polishing silicon wafers, special steel sheets
		Organic/Monomer Sol	film coating, antistatic interference shielding, electronic printing materials, resin additive
		Oilfield materials	for enhancing oil recovery
Agrochemicals	Herbicide	TARGA	soybean, rapeseed, sugarbeet
		PERMIT	corn, sugarcane, rice
		ROUNDUP	non-selective herbicide for orchard, noncrop land
		ALTAIR	rice
		VERDAD	rice
	Insecticide	GRACIA	vegetables, tea, fruits
	Fungicide	LEIMAY	potato, vegetables, grape
		DITHANE (MANCOZEB)	fruits, vegetables
	Animal health product	Fluralaner	active substance of BRAVECTO® (veterinary medical product for dogs and cats) and EXZOLT® (for poultry, cattle, and sheep)
Chemicals	Fine Chemicals	TEPIC	epoxy compound for LED sealants, solder resist, painting
		Melamine cyanurate	flame retardant
		Environmental related products	agent used for sterilizing, disinfectant for swimming pool and septic tanks, etc.
		FINEOXOCOL	cosmetics, lubricants, adhesive
	Basic Chemicals	Melamine (sales ended in December 2022)	adhesive agent
		AdBlue®	solution of urea in demineralised water for diesel vehicles to reduce NOx
		High purity sulfuric acid	agents used for cleaning semiconductors
		Ammonia, Sulfuric acid, Nitric acid, Urea	
Healthcare	LIVALO API		anti-cholesterol drug
	Custom Chemicals		custom manufacturing and solution proposal business for pharmaceutical companies

1. ARC® and OptiStack® are registered trade mark of Brewer Science, Inc.

2. BRAVECTO® and EXZOLT® are registered trade mark of MAH.

3. AdBlue® is a registered trademark of German Automobile Industry Association (Verband der Automobilindustrie).

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.

All rights reserved to Nissan Chemical Corporation.

